Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jan;138(1):91-8.
doi: 10.1038/sj.bjp.0705005.

Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex

Affiliations

Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex

Matteo Marti et al. Br J Pharmacol. 2003 Jan.

Abstract

1 The pharmacological profiles of presynaptic nociceptin/orphanin FQ (N/OFQ) peptide receptors (NOP) modulating 5-hydroxytryptamine (5-HT) and noradrenaline (NE) release in the rat neocortex were characterized in a preparation of superfused synaptosomes challenged with 10 mM KCl. 2 N/OFQ concentration-dependently inhibited K(+)-evoked [(3)H]-5-HT and [(3)H]-NE overflow with similar potency (pEC(50) approximately 7.9 and approximately 7.7, respectively) and efficacy (maximal inhibition approximately 40%). 3 N/OFQ (0.1 micro M) inhibition of [(3)H]-5-HT and [(3)H]-NE overflow was antagonized by selective NOP receptor antagonists of peptide ([Nphe(1)]N/OFQ(1-13)NH(2) and UFP-101; 10 and 1 microM, respectively) and non-peptide (J-113397 and JTC-801; both 0.1 microM) nature. Antagonists were routinely applied 3 min before N/OFQ. However, a 21 min pre-application time was necessary for J-113397 and JTC-801 to prevent N/OFQ inhibition of [(3)H]-NE overflow. 4 The NOP receptor ligand [Phe(1)psi(CH(2)-NH)Gly(2)]N/OFQ(1-13)NH(2) ([F/G]N/OFQ(1-13)NH(2); 3 microM) did not affect K(+)-evoked [(3)H]-NE but inhibited K(+)-evoked [(3)H]-5-HT overflow in a UFP-101 sensitive manner. [F/G]N/OFQ(1-13)NH(2) antagonized N/OFQ actions on both neurotransmitters. 5 The time-dependency of JTC-801 action was studied in CHO cells expressing human NOP receptors. N/OFQ inhibited forskolin-stimulated cAMP accumulation and JTC-801, tested at different concentrations (0.1-10 microM) and pre-incubation times (0, 40 and 90 min), antagonized this effect in a time-dependent manner. The Schild-type analysis excluded a competitive type of antagonism. 6 We conclude that presynaptic NO receptors inhibiting 5-HT and NE release in the rat neocortex have similar pharmacological profiles. Nevertheless, they can be differentiated pharmacologically on the basis of responsiveness to [F/G]N/OFQ(1-13)NH(2) and time-dependent sensitivity towards non-peptide antagonists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
N/OFQ inhibits synaptosomal [3H]-5-HT and [3H]-NE overflow. Concentration–response curves of the inhibitory effects of N/OFQ (0.001–3 μM) on 10 mM K+-evoked [3H]-5-HT and [3H]-NE overflow. Significant inhibition of [3H]-5-HT and [3H]-NE overflow was found at 10 nM N/OFQ. Data are expressed as per cent of the K+ stimulation and are means±s.e.mean of at least eight experiments.
Figure 2
Figure 2
Selective NOP receptor antagonists prevent N/OFQ inhibition of [3H]-5-HT overflow. Effects of [Nphe1], UFP-101, J-113397 and JTC-801 on the inhibition of K+-evoked [3H]-5-HT overflow induced by N/OFQ (0.1 μM). Antagonists were perfused 3 min before N/OFQ and maintained until the end of experiment. Data are means±s.e.mean of at least eight experiments. *P<0.05; different from control. aP<0.05; different from N/OFQ.
Figure 3
Figure 3
The NOP receptor ligand [F/G] prevents N/OFQ inhibition of [3H]-5-HT and [3H]-NE overflow. Effect of [F/G] (3 μM) on the inhibition of [3H]-5-HT and [3H]-NE overflow induced by N/OFQ (0.1 μM). [F/G] was applied (in the presence of naloxone 3 μM) 3 min before N/OFQ and maintained until the end of experiment. Data are means±s.e.mean of at least eight experiments. *P<0.05; different from control. aP<0.05; different from N/OFQ.
Figure 4
Figure 4
Selective peptide NOP receptor antagonists prevent N/OFQ inhibition of [3H]-NE overflow. Effect of [Nphe1] and UFP-101 on the inhibition of [3H]-NE overflow induced by N/OFQ (0.1 μM). Antagonists were perfused 3 min before N/OFQ and maintained until the end of experiment. Data are means±s.e.mean of at least six experiments. *P<0.05; different from control. aP<0.05; different from N/OFQ.
Figure 5
Figure 5
Selective non-peptide NOP receptor antagonists prevent N/OFQ inhibition of [3H]-NE overflow. Effect of J-113397 and JTC-801 on the inhibition of [3H]-NE overflow induced by N/OFQ (0.1 μM). Antagonists were applied at different times (3, 9 and 21 min) before N/OFQ and maintained until the end of experiment. Data are means±s.e.mean of at least six experiments. *P<0.05; different from control. aP<0.05; different from N/OFQ.
Figure 6
Figure 6
N/OFQ inhibits cAMP accumulation in CHOhNOP cells. The inhibitory effect of N/OFQ (0.001–1 μM) on forskolin-stimulated cyclic AMP accumulation in CHO cells expressing human recombinant NOP receptors was measured in the absence or the presence of the non-peptide NOP receptor antagonist JTC-801 (0.1–10 μM) at different pre-incubation times (0, 40 and 90 min; panel A, B and C, respectively). Data are means±s.e.mean of ⩾3 experiments.

References

    1. BIGONI R., CALO G., RIZZI A., GUERRINI R., DE RISI C., HASHIMOTO Y., HASHIBA E., LAMBERT D.G., REGOLI D. In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn Schmiedebergs Arch. Pharmacol. 2000;361:565–568. - PubMed
    1. BURNSIDE J.L., RODRIGUEZ L., TOLL L. Species differences in the efficacy of compounds at the nociceptin receptor (ORL1) Peptides. 2000;21:1147–1154. - PubMed
    1. CALO G., GUERRINI R., BIGONI R., RIZZI A., BIANCHI C., REGOLI D., SALVADORI S. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J. Med. Chem. 1998;41:3360–3366. - PubMed
    1. CALO G., GUERRINI R., RIZZI A., SALVADORI S., REGOLI D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 2000;129:1261–1283. - PMC - PubMed
    1. CALO G., RIZZI A., BIGONI R., GUERRINI R., SALVADORI S., REGOLI D. Pharmacological profile of nociceptin/orphanin FQ receptors. Clin. Exp. Pharmacol. Physiol. 2002a;29:223–228. - PubMed

Publication types

MeSH terms

LinkOut - more resources